The first Medicare Maximum Fair Prices took effect in January 2026. If you run a 340B program, you have probably already felt the impact — but you may not fully understand the mechanics behind it. Here is what is actually happening and what you need to do about it.
What Changed on January 1
Ten high-cost Part D drugs now have Medicare-negotiated prices under the Inflation Reduction Act. These Maximum Fair Prices apply when Medicare beneficiaries fill these drugs, and they directly collide with 340B pricing. The duplicate discount prohibition means you cannot receive both the 340B ceiling price and the MFP on the same drug unit. You get whichever is lower.
For most of the initial ten drugs, the MFP is lower than the 340B ceiling price. That means your 340B savings on those specific drugs for Medicare patients just shrank. This is not a theoretical concern — it is showing up in pharmacy P&L statements right now.
Quantify Your Exposure
The first step is understanding how much of your 340B savings come from the ten MFP drugs. Pull a report on your 340B dispenses for the past 12 months and filter for the negotiated drugs. Cross-reference against payer — only Medicare Part D claims are affected. If Medicare patients account for 15 percent of your 340B volume on these drugs, that is roughly the savings you are losing.
For most FQHCs, the initial exposure is modest — somewhere between $50,000 and $200,000 annually, depending on patient mix and formulary. But the program expands to 15 more drugs in 2027 and 15 more in 2028. The trajectory matters more than the current number.
The Operational Headache: Deduplication
CMS explicitly said it will not handle deduplication between 340B and MFP. That responsibility falls on the covered entity. If you dispense a negotiated drug to a Medicare patient at 340B pricing and the manufacturer also provides the MFP discount, you have a duplicate discount — and that is a compliance violation.
Your pharmacy system and TPA need to identify MFP-eligible claims and exclude them from 340B accumulation. If your systems cannot do this automatically, you need a manual reconciliation process. This is not optional.
Adjust Your Financial Projections
If your budget assumes flat or growing 340B savings, revise it now. Model three scenarios: current ten drugs only, 2027 expansion (25 drugs), and 2028 expansion (40 drugs). Use your actual patient mix and formulary data, not national averages. The organizations that get caught off guard will be the ones that treated MFP as someone else's problem until it appeared in their financials.
The Strategic Response
The 340B program is not going away, but its economics are changing. Covered entities that rely heavily on a small number of high-cost drugs for their 340B margin are the most exposed. The smart response is diversification: strengthen your capture rate on the hundreds of drugs that are not subject to MFP, optimize your in-house pharmacy operations, and build clinical programs that generate value independent of drug pricing spreads.
The MFP era rewards operational excellence over passive margin collection. That has always been the right way to run a 340B program. Now the math demands it.
Tools That Help You Navigate This
We built working prototypes for the exact operational challenges this article describes:
CoverageGuard IQ — Reconciles eligibility signals and manages the Medicaid recertification loop that determines whether a patient hits 340B or MFP pricing.
Board Intelligence — Translates 340B financial exposure into executive-ready dashboards your board can act on in 3 minutes.
13 working prototypes, all live. Explore them here →
Want to talk through your specific MFP exposure? Start a conversation →